Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
about
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@en
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@nl
type
label
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@en
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@nl
prefLabel
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@en
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@nl
P2093
P2860
P1476
Secukinumab improves active ps ...... ind, phase III FUTURE 5 study.
@en
P2093
Aimee Readie
Atul Singhal
Elke Boettcher
Hasan Tahir
Karin Meiser
Ken Abrams
Luminita Pricop
Philip Mease
Proton Rahman
Sandra Navarra
P2860
P304
P356
10.1136/ANNRHEUMDIS-2017-212687
P407
P577
2018-03-17T00:00:00Z